206 Combined administration of shikonin and cisplatin increases Fe2+, ROS, and lipid peroxidation (LPO) levels and downregulates GPX4 in ovarian cancer cells, reducing cisplatin resistance by inducing ferroptosis.207. This evidence concerns the gene GPX4 and ovarian carcinoma.